Axa S.A. Has $2.82 Million Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Axa S.A. boosted its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 409.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 96,689 shares of the life sciences company’s stock after buying an additional 77,697 shares during the period. Axa S.A. owned approximately 0.12% of Integra LifeSciences worth $2,818,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of IART. State of Michigan Retirement System increased its position in Integra LifeSciences by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 16,690 shares of the life sciences company’s stock worth $592,000 after purchasing an additional 400 shares during the last quarter. CWM LLC raised its holdings in Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 425 shares in the last quarter. Blue Trust Inc. raised its holdings in Integra LifeSciences by 100.5% in the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 444 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its holdings in Integra LifeSciences by 1.1% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 49,762 shares of the life sciences company’s stock valued at $1,764,000 after acquiring an additional 551 shares in the last quarter. Finally, Texas Permanent School Fund Corp raised its holdings in Integra LifeSciences by 1.5% in the 1st quarter. Texas Permanent School Fund Corp now owns 59,524 shares of the life sciences company’s stock valued at $2,110,000 after acquiring an additional 870 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on IART shares. BTIG Research dropped their target price on Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating for the company in a report on Wednesday, August 28th. Citigroup decreased their price objective on Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating for the company in a research note on Thursday, August 22nd. Morgan Stanley lifted their price objective on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research note on Monday, July 15th. JMP Securities decreased their target price on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research note on Tuesday, July 30th. Finally, Truist Financial decreased their target price on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating for the company in a research note on Tuesday, July 30th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Integra LifeSciences currently has an average rating of “Hold” and an average price target of $28.63.

Integra LifeSciences Stock Performance

IART opened at $17.87 on Monday. Integra LifeSciences Holdings Co. has a 52-week low of $16.96 and a 52-week high of $45.42. The firm has a market capitalization of $1.41 billion, a PE ratio of 35.74, a PEG ratio of 0.60 and a beta of 1.10. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. The business’s 50-day simple moving average is $21.33 and its 200 day simple moving average is $27.14.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.62 by $0.01. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The company had revenue of $418.20 million for the quarter, compared to the consensus estimate of $413.07 million. During the same quarter in the prior year, the business earned $0.71 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. As a group, sell-side analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.